Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial.
Breast · 2025-Apr · PMID 39954568
Overall survival
Kaplan–Meier estimates of investigator-assessed progression-free survival and overall survival. (a) progression-free survival and (b) overall survival in the intent-to-treat population ( n = 649); HLX02 ( n = 324), EU-trastuzumab ( n = 325). Tick marks indicate censoring of the data at the time of the last imaging assessment for PFS, and censoring of the data at the last known survival date for OS, respectively. Median survival and their 95 % CIs were derived using a Cox proportional hazard model with hormone receptor status, prior neo-/adjuvant therapy with trastuzumab, and ethnicity (Asian vs. non-Asian) as covariates. P-values were calculated using the stratified log-rank test. CI confidence interval, HR hazard ratio, NE not evaluable, NR not reached.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 1.0000 | 0.0000 | 100.0000 | 72 | 15 |
| 1 | 2 | 0.0853 | 1.0000 | 3.5814 | 100.0000 | 127 | 15 |
| 1 | 3 | 0.0868 | 0.9919 | 3.6465 | 99.1935 | 128 | 17 |
| 1 | 4 | 0.0884 | 0.9919 | 3.7116 | 99.1935 | 129 | 17 |
| 1 | 5 | 0.0899 | 0.9919 | 3.7767 | 99.1935 | 130 | 17 |
| 1 | 6 | 0.0915 | 0.9919 | 3.8419 | 99.1935 | 131 | 17 |
| 1 | 7 | 0.0930 | 0.9919 | 3.9070 | 99.1935 | 132 | 17 |
| 1 | 8 | 0.0946 | 0.9919 | 3.9721 | 99.1935 | 133 | 17 |
| 1 | 9 | 0.0961 | 0.9879 | 4.0372 | 98.7903 | 134 | 18 |
| 1 | 10 | 0.0977 | 0.9879 | 4.1023 | 98.7903 | 135 | 18 |
| 2 | 1 | 0.0000 | 1.0000 | 0.0000 | 100.0000 | 72 | 15 |
| 2 | 2 | 0.0713 | 1.0000 | 2.9953 | 100.0000 | 118 | 15 |
| 2 | 3 | 0.0729 | 1.0000 | 3.0605 | 100.0000 | 119 | 15 |
| 2 | 4 | 0.0744 | 1.0000 | 3.1256 | 100.0000 | 120 | 15 |
| 2 | 5 | 0.0760 | 1.0000 | 3.1907 | 100.0000 | 121 | 15 |
| 2 | 6 | 0.0775 | 1.0000 | 3.2558 | 100.0000 | 122 | 15 |
| 2 | 7 | 0.0791 | 1.0000 | 3.3209 | 100.0000 | 123 | 15 |
| 2 | 8 | 0.0806 | 1.0000 | 3.3860 | 100.0000 | 124 | 15 |
| 2 | 9 | 0.0822 | 1.0000 | 3.4512 | 100.0000 | 125 | 15 |
| 2 | 10 | 0.0837 | 1.0000 | 3.5163 | 100.0000 | 126 | 15 |
| 2 | 11 | 0.0853 | 0.9919 | 3.5814 | 99.1935 | 127 | 17 |
| 2 | 12 | 0.0868 | 0.9919 | 3.6465 | 99.1935 | 128 | 17 |
| 2 | 13 | 0.0884 | 0.9919 | 3.7116 | 99.1935 | 129 | 17 |
| 2 | 14 | 0.0899 | 0.9919 | 3.7767 | 99.1935 | 130 | 17 |
| 2 | 15 | 0.0915 | 0.9879 | 3.8419 | 98.7903 | 131 | 18 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-24T15:20:03+00:00 |